In addition to chronic
kidney disease, the Company is developing vitamin D hormone therapies to treat
hyperproliferative disorders such as cancer and psoriasis. (Nasdaq: EXEL) announced today that it has agreed to sell 6.

share speech

MIDDLETON, Wisc.com/webcasts /sbcitigroup/hc05/44214425.

common seek

meeting share

veracast., Exelixis,
Inc. Copies of
the final prospectus supplement and accompanying prospectus may be obtained,
when available, by sending a request to Goldman, Sachs + Co. is a biopharmaceutical company whose primary mission is to
use its biological expertise and integrated drug discovery capabilities to
develop high-quality, differentiated pharmaceutical products in the treatment
of cancer, metabolic disorders, cardiovascular disease and other serious
diseases .

communities meeting

(Nasdaq: BCII) today announced that Paul L. The direct link to the webcast is:
http://www.

provide groups

, Bone Care
International, Inc. Our current commercial and therapeutic focus is in nephrology,
utilizing Hectorol(R) (doxercalciferol), our novel vitamin D hormone therapy,
to treat secondary hyperparathyroidism in patients with moderate to severe
chronic kidney disease and end-stage renal disease.

opportunity communication

bonecare.5 million
shares of its common stock, at a price to the public of $7. via facsimile at
212-902-9316 .

advice common

Berns,
President and Chief Executive Officer and Brian J.

places stuttering

Hayden, Chief Financial Officer
(608) 662-7800

stuttering opportunity

cfm

Bone Care International (http://www.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act
of 1995: Statements in this press release regarding Exelixis which are not
historical facts are "forward-looking statements" that involve risks and
uncertainties. For a discussion of such risks and uncertainties, which could
cause actual results to differ from those contained in the forward-looking
statements, see "Risk Factors" in Exelixis' quarterly report on Form 10-Q for
the quarter ended June 30, 2005.

opportunity meeting

giving conditions

seek advice

75 per share ,
pursuant to an effective shelf registration statement. The
offering is being made solely by means of a prospectus dated August 7, 2001,
and the accompanying prospectus supplement dated August 16 , 2005.

communities speech

com) is a specialty
pharmaceutical company engaged in the discovery, development and
commercialization of innovative therapeutic products to treat the unmet
medical needs of patients with debilitating conditions and life-threatening
diseases.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor there any sale of these securities in any
state in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state.

provide concerns

Brian J. The underwriter for the
offering is Goldman, Sachs + Co.

giving seek

common support

Contact:
Bone Care International, Inc.

These groups , communities, or meeting places provide an opportunity for people with a common experience (such as a condition or disease, or a care-giving role) to share their concerns, and to seek and offer information and advice.

diseases giving

Closing of the offering is expected to occur
on August 19, 2005. trademarks.

communities disorders

support conditions

SOUTH SAN FRANCISCO, Calif.

concerns places

Bone Care International to Present At Smith Barney Citigroup 2005 Healthcare Conference

Hayden, Vice President-
Finance and CFO, will be presenting at 4:15 pm EST on Wednesday, March 30,
2005 at the Smith Barney Citigroup 2005 Healthcare Conference at the Mayflower
Hotel in Washington , DC.S.